Stock Report

All about this stock under one free report Last Updated: 07-Sep-2026

Stock Rating

Is this stock worth it? Our ratings reveal the truth.

Wealth Insight New Issue

Serious stock insights. No fluff. No FOMO.

Recently Viewed

Clear All

Lantheus Holdings (LNTH) Peer Comparison

Stock Card factsheet share-fund-plan-icon

$100.97

up-down-arrow $-0.01 (-0.01%)

As on 04-Sep-2026 16:00EDT

Market cap

info icon

$6,591 Mln

Revenue (TTM)

info icon

$1,556 Mln

P/E Ratio

info icon

24.2

P/B Ratio

info icon

5

Div. Yield

info icon

0 %

Edit peer-selector-edit
Lantheus Holdings (LNTH) Penumbra (PEN) Glaukos Corp (GKOS) Bio-Rad Laboratories Repligen (RGEN)
Market cap ($ Mln)
 6,591 12,650 10,638 9,762 9,459
Revenue ($ Mln)
 1,556 1,505 613 2,589 785
Net Profit ($ Mln)
 275.31 160.59 -188.05 222.40 41.54
Net Margin (%)
 17.69 10.67 -30.68 8.59 5.29
RoE (%)
 22.93 10.86 -28.10 3.04 1.97
Price to Earnings
 24.16 79.29 -- 44.47 232.78
Price-To-Book
 5.02 8.31 15.27 1.36 4.62

Income Statement ($ Mln)

Lantheus Holdings (LNTH) Penumbra (PEN) Glaukos Corp (GKOS) Bio-Rad Laboratories Repligen (RGEN)
Operating Revenue arrow
1,556.31 1,504.87 612.84 2,589.30 785.10
Cost of Revenue arrow
620.30 483.98 127.96 1,245.50 384.30
Gross Profit arrow
941.95 942.44 393.22 1,343.60 347.62
Operating Expenses arrow
633.68 833.56 565.37 1,108.90 335.50
Operating Profit (EBIT) arrow
302.34 187.34 -80.49 235.00 65.30
Other Income arrow
0.00 0.00 0.00 0.00 0.00
Profit before Tax arrow
362.98 203.83 -192.83 350.40 52.15
Provision for Tax arrow
87.67 43.24 -4.79 128.00 10.61
Profit after Tax (Net Income) arrow
275.31 160.59 -188.05 222.40 41.54
Minority Interest arrow
0.00 0.00 0.00 0.00 0.00
Consolidated Profit arrow
0.00 93.19 0.00 0.00 0.00

Liabilities ($ Mln)

Lantheus Holdings (LNTH) Penumbra (PEN) Glaukos Corp (GKOS) Bio-Rad Laboratories Repligen (RGEN)
Shareholder's Funds arrow
1,311.78 1,530.77 682.49 7,173.90 2,112.03
Minority Interest arrow
0.00 0.00 0.00 0.00 0.00
Non-Current Liabilities arrow
767.21 210.18 135.71 2,116.80 705.49
Current Liabilities arrow
335.68 233.78 102.33 961.30 132.66
Total Liabilities arrow
2,227.40 1,826.52 893.49 10,576.50 2,949.70

Assets ($ Mln)

Lantheus Holdings (LNTH) Penumbra (PEN) Glaukos Corp (GKOS) Bio-Rad Laboratories Repligen (RGEN)
Non-Current Assets arrow
1,387.60 630.60 404.74 7,231.50 1,749.63
Current Assets arrow
1,027.06 1,344.12 515.78 3,020.50 1,200.55
Total Assets arrow
2,227.40 1,826.52 893.49 10,576.50 2,949.70
Total Debt* arrow
624.96 212.71 102.84 1,203.70 690.94
Net Current Assets arrow
691.38 1,110.35 413.45 2,059.20 1,067.90

Cashflow ($ Mln)

Lantheus Holdings (LNTH) Penumbra (PEN) Glaukos Corp (GKOS) Bio-Rad Laboratories Repligen (RGEN)
Cash From Operating Activities arrow
390.14 238.66 -46.34 532.20 117.42
Cash Flow from Investing Activities arrow
-627.17 -404.59 -77.61 -189.70 -298.47
Cash from Financing Activities arrow
-316.58 26.53 11.89 -283.20 -15.21
Net Cash Inflow / Outflow arrow
-- -- -- -- --

Ratios

Profitability Ratios

 Lantheus Holdings (LNTH) Penumbra (PEN) Glaukos Corp (GKOS) Bio-Rad Laboratories Repligen (RGEN)
ROCE (%) arrow
13.67 11.76 -22.53 8.98 1.79
ROE (%) arrow
22.93 10.86 -28.10 3.04 1.97
ROA (%) arrow
10.70 7.95 -18.00 2.02 1.36
EBIT Margin (%) arrow
24.60 13.63 -30.58 -5.99 9.87
Net Margin (%) arrow
17.69 10.67 -30.68 8.59 5.29
Cash Profit Margin (%) arrow
0.00 0.00 0.00 0.00 0.00

Growth Ratios

 Lantheus Holdings (LNTH) Penumbra (PEN) Glaukos Corp (GKOS) Bio-Rad Laboratories Repligen (RGEN)
Revenue Growth (%) arrow
2.35 17.55 41.55 1.37 16.49
EBIT Growth (%) arrow
-3.35 17.49 -116.42 -131.06 920.91
Net Profit Growth (%) arrow
1.59 8.72 -102.66 -30.32 400.42
EPS Growth (%) arrow
9.91 8.12 -96.88 -29.66 394.30
Book Value Growth (%) arrow
17.08 17.33 -12.65 2.19 2.16

Valuation Ratios

 Lantheus Holdings (LNTH) Penumbra (PEN) Glaukos Corp (GKOS) Bio-Rad Laboratories Repligen (RGEN)
Price / Earnings arrow
18.90 68.93 -34.59 -- 189.42
Price / Book Value arrow
5.02 8.31 15.27 -- 4.62
Dividend Yield (%) arrow
0.00 0.00 0.00 -- 0.00
EV/EBITDA arrow
14.72 55.45 -73.80 -- 77.00
Market Cap ($ Cr) arrow
-- -- -- -- --

Solvency Ratios

 Lantheus Holdings (LNTH) Penumbra (PEN) Glaukos Corp (GKOS) Bio-Rad Laboratories Repligen (RGEN)
Debt to Equity arrow
0.43 0.00 0.00 0.11 0.26
Short term debt to equity ratio arrow
0.00 0.01 0.00 0.06 0.01
Current Ratio arrow
3.06 5.75 5.04 3.14 9.05
Quick Ratio arrow
2.89 3.86 4.46 2.33 7.64
Interest Coverage arrow
19.33 157.91 -38.31 8.18 1.92

Operating Efficiency Ratios

 Lantheus Holdings (LNTH) Penumbra (PEN) Glaukos Corp (GKOS) Bio-Rad Laboratories Repligen (RGEN)
Debtors to sales (%) arrow
22.67 12.65 22.67 17.06 20.09
Asset Turnover arrow
0.60 0.74 0.59 0.24 0.26
Receivable days arrow
80.54 46.54 60.95 65.39 72.41
Inventory Days arrow
40.41 331.92 193.84 221.09 146.53
Payable days arrow
23.59 26.16 60.19 37.02 29.05
Cash Conversion Cycle arrow
97.36 352.30 194.60 249.46 189.88
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
loading...
loading...